Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions

Journal of Clinical Pharmacology

Volumn 48, Issue 6, 2008, Pages 671-680

  Penzak, Scott R ^a,b   Busse, Kristin H ^a   Robertson, Sarah M ^a   Formentini, Elizabeth ^b   Alfaro, Raul M ^a   Davey Jr , Richard T ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

CYP3A; Drug interactions; Ginkgo biloba extract; Midazolam

Indexed keywords

ALPRAZOLAM; CYTOCHROME P450 3A; GINKGO BILOBA EXTRACT; HALOPERIDOL; MIDAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONFIDENCE INTERVAL; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GEOMETRY; HUMAN; HUMAN EXPERIMENT; LINEAR REGRESSION ANALYSIS; MALE; NORMAL HUMAN; PREDICTION; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; FEMALE; FORECASTING; GINKGO BILOBA; HERB-DRUG INTERACTIONS; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDAZOLAM; MIDDLE AGED; PLANT EXTRACTS; TIME FACTORS;

EID: 44049088374     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008317305     Document Type: Article

References (15)

1. Kashuba A., Bertino J. Mechanisms of drug interactions I. In: Piscitelli SC, Rodvold KA, eds. Drug Interactions in Infectious Diseases. 2 nd ed. Totowa, NJ: Humana ; 2005: 13-39.
2. Streetman DS, Bertino JS, Nafziger AN Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000 ; 10: 187-216.
3. Rogers JF, Nafziger AN, Kashuba AD, et al. Single plasma concentrations of 1′-hydroxymidazolam or the ratio of 1′-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects. J Clin Pharmacol. 2002 ; 42: 1079-1082.
4. Eap CB, Buclin T., Cucchia G., et al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol. 2004 ; 60: 237-246.
5. American Herbal Pharmacopoeia; Analytical Methods Review SOP. Available at: http://www.herbal-ahp.org/method_commit.htm. Accessed May 23, 2007.
6. Lin YS, Lockwood GF, Graham MA, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics. 2001 ; 11: 781-791.
7. Krupka E., Venisse N., Lafay C., et al. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers. Eur J Clin Pharmacol. 2006 ; 62: 653-659.
8. Chaobal HN, Kharasch ED Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin Pharmacol Ther. 2005 ; 78: 529-539.
9. Sheiner LB, Beal SL Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981 ; 9: 503-512.
10. Kim JS, Nafziger AN, Tsunoda SM, et al. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol. 2002 ; 42: 376-382.
11. Allonen H., Ziegler G., Klotz U. Midazolam kinetics. Clin Pharmacol Ther. 1981 ; 30: 653-661.
12. Nafziger AN, Bertino JS Jr. Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis. Clin Pharmacol Ther. 2007 ; 82: 379.
13. Kaneshiro Y., Oda Y. Response to Nafziger and Bertino. Clin Pharmacol Ther. 2007 ; 82: 380.
14. Versed (midazolam HCl syrup) [product information]. Nutley, NJ: Roche Pharmaceuticals ; 1998.
15. Bornemann LD, Crews T., Chen SS, et al. Influence of food on midazolam absorption. J Clin Pharmacol. 1986 ; 26: 55-59.